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This book is organized into five main sections, which follow a of cancer or leukacmia and is associated with the overproduction 
good comprehensive introductory chapter. The first section of the integral membrane P-glycoprotein. The resistance 
(chapters 2-7) covers the basic aspects of the genetics and associated with DNA topoisomerases, however, appears to be 
biochemistry of prokaryotic and eukaryotic DNA topoisomerascs related to altered rquirsments of the topoisomerase nzymes and 
I and II, This section includes an examination in chapter 6 of is denoted as atMDR where ‘at’ is altered topoisomerase (chapter 
inhibitors of bacterial DNA gyrase such as the ctoposide VP-16, 21). Finally, the fifth section (chapters 23-25) deals with the 
which may offer a new approach to antitrypanosomal development and clinical use of topoisomerase inhibitors. These 
chemotherapy. The use of yeast permeability mutants as a genetic are used in the chemotherapy of patients with locally advaneed or 
system that facilitates the study of antilumour drugs such as metastatic olon cancer. It has been found that two derivatives of 
camptothecin, etoposides and teniposides targeted at DNA camptothecin, 9-amino-ZO(RS) and 10,l l-methylene-dioxy- 
topoisomerases is discussed in chapter 7. Purified yeast DNA 20(RS) give long-term disease-free remissions and are of low 
topoisomerases I and II are similar to their mammalian toxicity (chapter 24). They also appear lo by-pass the problem of 
counterparts in their interaction with these antitumour agents. cellular resistance mechanism in cancer cells. 
The second section of this book (chapters t-15) examines 
inhibitors of topoisomerasc I, including the natural product 
campothecin. This ia followed by a third section on inhibitors of 
topoisomerase II (chapters 16-19) The modification of the effects 
of topoisomerase inhibitors by the presence of other DNA binders 
such as polyamines is alo considered. The clinical problem of the 
resistance of cancer cell topoisomerases to the drugs against them 
is the theme of the fourth section (chapters 20-22). Multidrug 
resistance (MDR) is a particularly serious problem in many types 
This comprehensive volume deals in depth with a wide range of 
topics relating to DNA topoisomcrase with particular emphasis 
on the relationship to cancer chemotherapy. The individual 
chapters are well documented and there is an adquate index. This 
book will be of great use as a source of both background reading 
and detailed material on this important subject area where cell 
biology and enzymology advance cancer therapies. 
Helen Wiseman 
New Drugs for Asthma Therapy (Agents and Actions supplements, vol 34); Edited by G.P. Anderson, I.D. Chapman and 
J. Morley; Birckhauser-Verlag; BaseUBoston/Berlin, 1991; x + 548 pages, Sw.Fr.148.00 
This book conslitutes the proceedings of an IUPHAR satellite 
symposium entitled ‘New Drugs for Asthma’ organ&d by the 
editors, Anderson, Chapman and Morley, in 1990. The title is 
somewhat misleading since the majority of papers discuss the 
pharmacology of compounds under early investigation by various 
pharmaceutical companies. Furthermore, approximately 25% of 
the papers do not discuss any therapy for asthma, potential or 
otherwise, but focus on the use of animal preparations, usually 
guinea-pigs, to evaluate novel therapies. 
The book is divided into four sections, the first being devoted 
to bronchodilator drugs. Three papers review recent advances in 
the area of &adrenoceptor agonists, which have led to the 
development of two long-acting compounds, salmeterol and 
formoterol, and the terbutaline pro-drug, bambuterol. These 
agents clearly provide the standard against which any novel 
brocchodilator agent will have to be astissed. Furthermore, 
evidence suggests that the new, long-acting &adrcnoceptor 
agonist, salmeterol, may possess clinically useful anti- 
inflammatory actions, which the short-acting compounds do no. 
Against this background, the other papers in the section address 
the therapeutic potential of selective phosphodiesterase inhibitors, 
muscarinic agonists and potassium channel opening agents. 
Unfortunately, few of these agents have been extensively evaluated 
in man, and their true therapeutic potential remains unclear. 
The next two sections of this book are devoted to ‘Inhibitors of 
Allergic Mediators as Targets’ and ‘Prophylactic Anti-Asthmatic 
Drugs’, respectively, They contain a series of papers which 
describe different approaches aimed at either preventing the 
generation and release of pharmacological mediators, or blockiag 
the action of specific mediators. One highlight in this section is 
data from clinical studies with the thromboxane receptor 
antagonist, GR32191. It appears to demonstrate that throm- 
boxane receptor activation is not important in asthmatic 
bronchoconstriction. The rest of Ihe papers in this section describe 
the clinical and animal pharmacology of leukotriene receptor 
antagonists and inhibitors of lcukotriene synthesis, and the 
evaluation of a number of PAF receptor antagonists, anti- 
histamines and a range of agents of undefined mechanism. which 
modify various aspects of allergic reactions in sensitised animals. 
Notable omissions from these sections are papers on the 
pharmacology of tachykinin antagonists, an equally valid 
approach to a specific inhibitor of a putative allergic mediator, and 
an overview of the pharmacology ofglucocorticoids, agents which 
currently account for the majority of prophylactic therapy in 
asthma. 
The remainder of the book, in a se&on entitled ‘New 
approaches to Anti-Asthma Drug Deteelinn’, is a collection cf 
papers outlining methods of evaluating prospective therapies in 
animal preparations, The highlight of this section is a paper 
describing studies on the expression of the leukocyte adhesion 
molecules ICAM- and ELAM-1 during the response of sensitisecl 
primates to allergen, and the cffeet of antisera to these molecules 
on inflammatory cell recruitment and bronchial hyperreactivity. 
In this paper the case is made for an inhibitor of ICAM- as a 
therapy for asthma. 
In conclusion, this book may be of interest to those engaged in 
or cnterir:g the area of asthma research. However, the price seems 
rather high for a book which is already two years old. Therefore, 
I suspect more copies will be found in libraries than in personal 
dcXii0ilS. 
C.J. Whelan 
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